$XFOR
X4 Pharmaceuticals, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$2.79
▲+7.72%+$0.200
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateX4 Pharmaceuticals, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is XFOR up today? It is at $2.79 (+7.72%), and our scanner flagged it 45 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment XFOR spikes, and full due diligence on XFOR — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $XFOR 45 times in the last 30 days. Create a free account to track $XFOR, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on XFOR from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
Likely catalystX4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Oct 19, 2026 · todayThe company is cleared to issue new shares on demand, but has not yet. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Active shelf on file — the company can issue new shares on demand (valid ~3 years)
About $300.0M in size
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Kirske David Officer | Sold (automatic/other) | -12K 0.01% of company | sold 7.0% | 156K | $34K at $2.86 | Oct 1, 26 |
Craig Adam R Officer | Sold (automatic/other) | -47K 0.05% of company | sold 13% | 329K | $211K at $4.44 | Aug 12, 26 |
Volpone John Officer | Sold (automatic/other) | -25K 0.02% of company | sold 8.5% | 265K | $109K at $4.44 | Aug 12, 26 |
Kirske David Officer | Sold (automatic/other) | -9K | sold 4.8% | 168K | $36K at $4.26 | Jun 30, 26 |
Kirske David Officer | Sold (automatic/other) | -17K 0.02% of company | sold 8.8% | 176K | $73K at $4.29 | May 12, 26 |
Craig Adam R Officer | Bought (open market) | +86K 0.09% of company | added 30% | 376K | $250K at $2.90 | Oct 23, 25 |
Kirske David Officer | Acquired (grant/award) | +193K 0.2% of company | n/a | 193K | n/a | Aug 14, 25 |
Craig Adam R Officer | Acquired (grant/award) | +290K 0.3% of company | n/a | 290K | n/a | Aug 14, 25 |
Volpone John Officer | Acquired (grant/award) | +290K 0.3% of company | n/a | 290K | n/a | Aug 14, 25 |
Wyzga Michael S Director | Acquired (grant/award) | +2K | added 37% | 6K | n/a | Jun 9, 25 |
Mcgirr David W J Director | Acquired (grant/award) | +2K | added 47% | 5K | n/a | Jun 9, 25 |
Woods Keith Director | Acquired (grant/award) | +2K | added 33% | 6K | n/a | Jun 9, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on XFOR from our scanner (live price and day move above). A move this size is almost always tied to a specific catalyst. Most of the time that is an earnings report, a guidance update, or a company announcement. If none is shown above, the release may not be in our news feed yet. It will show up here as soon as it is.
XFOR last traded at $2.79, up 7.72% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
X4 Pharmaceuticals, Inc. Common Stock (XFOR) is next expected to report earnings on Wednesday, November 4, 2026, about 16 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The XFOR Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged XFOR 45 times in the last 30 days.
XFOR (X4 Pharmaceuticals, Inc. Common Stock) trades on XNAS, with a market cap of about $273M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge XFOR for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$XFOR discussion
Sign in to ask a question or join the discussion.